Adulterated protein supplements can lead to unintentional doping. This review outlines detection strategies and protective measures for athletes and clinicians.

Breast cancer is the most common cancer among women worldwide (WHO, 2023). The Dr. Margarete Fischer-Bosch Institute of ...

Clinicians need to familiarize themselves with menopause genitourinary symptom management so they can address the pressing medical needs of millions of women.

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

Adding Kisqali (ribociclib) to a nonsteroidal aromatase inhibitor helped patients with hormone receptor–positive, HER2-negative early breast cancer live longer without their disease returning, ...

Ribociclib plus nonsteroidal aromatase inhibitor therapy reduces the risk for invasive disease recurrence by 28.5% compared with nonsteroidal aromatase inhibitor ...

I am a healthy 69-year-old female. I walk every day and belong to an exercise group that I attend twice a week. I’m writing ...

Inluriyo is approved for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer after prior endocrine therapy failure. The EMBER-3 trial showed Inluriyo reduced cancer progression or death ...

“Treatment plays a significant role in long-term health after breast cancer; however, prevention is even more important and ...

Findings showed denosumab-kyqq demonstrated similar quality, safety, and efficacy to the reference product. Bosaya is approved to treat postmenopausal women with osteoporosis at high risk for fracture ...

Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD). Like the first oral SERD, Lilly’s imlunestrant is only cleared to treat ER-positive, HER2-negative ...

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to ...